Ballatori N. , Wang W., Lieberman MW (1998). Accelerated methylmercury elimination in y-glutamyl transpeptidase-deficient mice. Am J Pathol152: 1049-1055.
2.
Battalora M. , Tennant R. (1999). The use of transgenic mice in mutagenesis and carcinogenesis research and in chemical safety assessment . In: Molecular Biology of the Toxic Response , Puga A, Wallace K (eds). Taylor and Francis, Philadelphia , pp 111-126.
3.
Cadet JL, Sheng P., Ali S., Rothman R., Carlson E., Epstein C. (1994). Attenuation of methamphetamine-induced neurotoxicity in copper/ zinc superoxide dismutase transgenic mice. J Neurochem62: 380-383.
4.
Campbell IL , Chiang CS (1995). Cytokine involvement in CNS disease: Implications from transgenic mice. Ann NY Acad Sci771: 301-312.
5.
Cressman DE , Greenbaum LE, DeAngelis RA, Ciliberto G. Furth EE, Poli V., Taub R. ( 1996). Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science274: 1379-1383.
Friedberg EC , Meira LB, Cheo DL ( 1998). Database of mouse strains carrying targeted mutations in genes affecting cellular responses to DNA damage . Mutat Res407: 217-226.
8.
Gonzalez F., Fernandez-Salguero P., Lee S., Pineau T., Ward J. ( 1995). Xenobiotic receptor knockout mice. Toxicol Lett82/83: 117-121.
9.
Lee S., Buters J., Pineau T., Fernandez-Salguero P., Gonzalez F. (1996). Role of CYP2E1 in the hepatotoxicity of acetaminophen . J Biol Chem271: 12063-12067.
10.
Liang Hcl, Li H., McKinnon RA, Duffy JJ, Potter SS, Puga A., Nebert DW (1996). Cypla2(—/—) null mutant mice develop normally but show deficient drug metabolism. Proc Natl Acad Sci USA93: 1671-1676.
11.
Lindzey J., Korach K. (1997). Developmental and physiological effects of estrogen receptor gene disruption in mice. TEM8: 137-145.
12.
Lomnitski L. , Kohen R., Chen Y., Shohami E., Trembovler V., Vogel T., Michaelson M. (1997). Reduced levels of antioxidants in brains of apolipoprotein E-deficient mice following closed head injury . Pharmacol Biochem Behav56: 669-673.
13.
Mahler JF, Davis BJ, Morham SG, Langenbach R. (1996). Disruption of cyclooxygenase genes in mice. Toxicol Pathol24: 717-719.
14.
Maronpot RR (2000). The use of genetically modified animals in carcinogenicity bioassays. Toxicol Pathol28:450-453 (this issue).
15.
Nebert D. Duffy J (1997). How knockout mouse lines will be used to study the role of drug-metabolizing enzymes and their receptors during reproduction and development, and in environmental toxicity, cancer, and oxidative stress. Biochem Pharmacol53: 249-254.
16.
Pinkert C. (1997). The history and theory of transgenic animals. Lab Anim26: 29-34.
17.
Przedborski S., Kostic V., Jackson-Lewis V., Naini AB, Simonetti S., Fahn S., Carlson E., Epstein CJ, Cadet JL (1992). Transgenic mice with increased copper/zinc superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity . J Neurosci12: 1658-1667.
18.
Ryffel B. (1995). Cytokine knockout mice: Possible application in toxicological research. Toxicology105: 69-80.
19.
Tu P., Gurney ME, Julien JP, Lee VM, Trojanowski JQ (1997). Oxidative stress, mutant SOD1, and neurofilament pathology in transgenic mouse models of human motor neuron disease. Lab Invest76: 441-456.
20.
Valentine JL , Lee SS, Seaton MJ, Asgharian B., Farris G., Corton JC, Gonzalez FJ, Medinsky MA (1996). Reduction of benzene metabolism and toxicity in mice that lack cyp2e 1 expression . Toxicol Appl Pharmacol141: 205-213.
21.
Ward JM, Peters JM, Perella CM, Gonzalez FJ (1998). Receptor and nonreceptor-mediated organ-specific toxicity of di(2ethylhexyl) phthalate (DEHP) in peroxisome-proliferator-activated receptorα-null mice. Toxicol Pathol26: 240-246.
22.
Yamada Y., Fausto N. (1998). Deficient liver regeneration after carbon tetrachloride injury in mice lacking type 1 but not type 2 tumor necrosis factor receptor . Am J Pathol152: 1577-1589.
